Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.
Egan AC, Kronbichler A, Neumann I, Bettiol A, Carlson N, Cid MC, Emmi G, Gopaluni S, Harper L, Hauser T, Little MA, Luqmani RA, Mahr A, McClure M, Mohammad AJ, Nelveg-Kristensen KE, Ohlsson S, Peh CA, Rutherford M, Alamo BS, Scott J, Segelmark M, Smith RM, Szpirt WM, Tomasson G, Trivioli G, Vaglio A, Walsh M, Wester Trejo M, Westman K, Bajema IM, Jayne DRW. Egan AC, et al. Among authors: rutherford m. Kidney Int Rep. 2022 May 25;7(8):1745-1757. doi: 10.1016/j.ekir.2022.05.018. eCollection 2022 Aug. Kidney Int Rep. 2022. PMID: 35967106 Free PMC article.
Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study.
Rutherford MA, Scott J, Karabayas M, Antonelou M, Gopaluni S, Gray D, Barrett J, Brix SR, Dhaun N, McAdoo SP, Smith RM, Geddes CC, Jayne D, Luqmani R, Salama AD, Little MA, Basu N; UK and Ireland Vasculitis Rare Disease Group (UKIVAS). Rutherford MA, et al. Arthritis Rheumatol. 2021 Sep;73(9):1713-1719. doi: 10.1002/art.41728. Epub 2021 Jul 27. Arthritis Rheumatol. 2021. PMID: 33750043 Free PMC article.
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying.
Gisslander K, Rutherford M, Aslett L, Basu N, Dradin F, Hederman L, Hruskova Z, Kardaoui H, Lamprecht P, Lichołai S, Musial J, O'Sullivan D, Puechal X, Scott J, Segelmark M, Straka R, Terrier B, Tesar V, Tesi M, Vaglio A, Wandrei D, White A, Wójcik K, Yaman B, Little MA, Mohammad AJ; FAIRVASC consortium. Gisslander K, et al. Among authors: rutherford m. Ann Rheum Dis. 2024 Jan 2;83(1):112-120. doi: 10.1136/ard-2023-224571. Ann Rheum Dis. 2024. PMID: 37907255 Free PMC article.
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis.
Scott J, White A, Walsh C, Aslett L, Rutherford MA, Ng J, Judge C, Sebastian K, O'Brien S, Kelleher J, Power J, Conlon N, Moran SM, Luqmani RA, Merkel PA, Tesar V, Hruskova Z, Little MA. Scott J, et al. Among authors: rutherford ma. RMD Open. 2024 Apr 30;10(2):e003962. doi: 10.1136/rmdopen-2023-003962. RMD Open. 2024. PMID: 38688690 Free PMC article.
Reply.
Rutherford MA, Basu N. Rutherford MA, et al. Arthritis Rheumatol. 2022 Apr;74(4):725-726. doi: 10.1002/art.42024. Epub 2022 Feb 21. Arthritis Rheumatol. 2022. PMID: 34783446 Free PMC article. No abstract available.
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group. Barnes E, et al. Nat Med. 2023 Jul;29(7):1760-1774. doi: 10.1038/s41591-023-02414-4. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414897 Free PMC article.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 May 8:S2665-9913(24)00065-1. doi: 10.1016/S2665-9913(24)00065-1. Online ahead of print. Lancet Rheumatol. 2024. PMID: 38734019 Free article.
813 results